Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001572 · ClinicalTrials.gov registry record · Phase 1
Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT00001572: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00001572 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 21 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00001572, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
Patients undergo chemotherapy until remission is obtained, or disease has been stable for two cycles of chemotherapy, or progressive disease develops. Three to six months after completion of chemotherapy, patients who have achieved complete clinical remission or minimal disease status receive a series of 5 injections (given 1-2 months apart) of a vaccine consisting of 0.5 mg autologous tumor-derived immunoglobulin (Id) conjugated to KLH. The vaccine is administered with subcutaneous QS-21 as an immunological adjuvant....
Interventions
- DRUG Id-KLH Vaccine
- DRUG QS-21 (Stimulation-QS-21) Drug
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 1997-01-30 |
| Est. Completion | 2010-11-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001572
The ClinicalTrials.gov registry entry for NCT00001572 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Id-KLH Vaccine is the first listed.
NCT00001572 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00001572 about?
NCT00001572 is a clinical study titled "Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype". Patients undergo chemotherapy until remission is obtained, or disease has been stable for two cycles of chemotherapy, or progressive disease develops. Three to six months after completion of chemotherapy, patients who have achieved complete clinical remission or minimal disease status receive a ser...
What is the current status of trial NCT00001572?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 1997-01-30. Estimated completion is 2010-11-02.
What interventions are being tested in trial NCT00001572?
The interventions under investigation include: Id-KLH Vaccine (DRUG), QS-21 (Stimulation-QS-21) Drug (DRUG).
Who is sponsoring clinical trial NCT00001572?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.